MedTrace Logo

A Phase IIb Trial of Pulmicort Turbuhaler (Budesonide)

NCT00175747 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2005-09-15

No results posted yet for this study

Summary

Studies in animals suggest that inhaled budesonide may prevent the occurrence of lung cancer. We conducted a clinical trial to determine the effects of inhaled budesonide in smokers who had precancerous lesions in the breathing tubes (i.e. bronchial dysplasia.

Conditions

Interventions

DRUG

Inhaled Budesonide 800 µg twice daily

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • University of British Columbia

    lead OTHER

Principal Investigators

  • Stephen Lam, MD · University of British Columbia

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2000-01-31
Completion
2002-12-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00175747 on ClinicalTrials.gov